A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile
Key facts
- Who runs it
- Miguel O'Ryan Gallardo
- Where
- Chile3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- 2 Aug 2022
- Expected to end
- Aug 2027
- Type of study
- Interventional, 3 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Lansoprazole
- Amoxicillin
- Clarithromycin
- Metronidazole
- Record updated
- 17 December 2025
Who can take part
- Age
- 14 years to 18 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Healthy teenagers 14-18 years of age from Colina, Temuco or Coyhaique
- At least one responsible adult family member accessible for phone contact
- Persistent H. pylori infection determined by at least 2 positive UBT tests in a 3 months period (except for Non-infected Controls)
Who cannot take part
- Prior eradication therapy
- Antimicrobial course received during the previous month (at least 3 days of treatment at appropriate dosing, children meeting this criteria can be included at a later stage)
- Use of immunosuppressive or biologic drugs
- Known allergy to any of the antimicrobials used in the trial protocol (except for Non-infected Controls)
- Teenagers not consenting to treatment will be invited to continue as non-treated controls
- Signs/symptoms compatible with organic abdominal pain according to Rome IV criteria: persistent right upper or right lower quadrant pain, dysphagia, odynophagia, persistent vomiting, gastrointestinal blood loss, involuntary weight loss, deceleration of linear growth, delayed puberty
- Pregnancy
- Children deemed "not healthy" after review of the questionnaire by study physician
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Helicobacter pylori infection
This trial is currently available in Chile.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Gastric cancer remains a global health problem, and Chile has one of the highest GC mortality rates in the region. Helicobacter pylori (H. pylori) infection is ubiquitous in Chilean adults, and it constitutes the main cause of GC worldwide. A long-term process occurs from premalignant lesions to carcinoma. H. pylori eradication during early stages of disease significantly impacts outcomes, favoring survival, disease reversal and molecular changes, which supports a "screen and treat" strategy in asymptomatic populations in areas with intermediate-to-high GC prevalence. The Investigators' previous research has shown that H. pylori infection is acquired in early childhood with low rates of spontaneous eradication. A pilot treatment study in a subset of school-aged asymptomatic children showed a high rate of successful eradication (>95%), good tolerance, and was associated with a decrease in serum biomarkers of gastric damage (pepsinogen I and II). Based on the results of these studies, the Investigators propose to advance towards the next stage of this research process: a "screen and treat" strategy. The current trial starts with a Screening phase testing up to 1000 asymptomatic adolescents 14-18 years of age from 3 cities of Chile (Colina, Temuco and Coyhaique), to find a total of 210 persistently-infected participants. Persistently-infected adolescents will be included in a Second phase of this trial: A randomized, case-control, non-blinded study to either receive antimicrobial treatment targeting H. pylori eradication (cases) or no treatment (controls). A subset of 60 non-infected adolescents will be followed-up in matched times. This aims to provide evidence on the effect of treatment on clinical outcomes and serum biomarkers related to gastric damage, as well as composition and antimicrobial resistance of gut microbiota. The Investigators expect that eradication therapy will be successful in >90% of persistently infected adolescents, with reinfection rates not surpassing 15% in a 2-3 year period, and to be associated with a decrease in clinical findings indicative of gastric disease, and a decrease in serum biomarker indicative of "gastric damage".
The 3 groups in the trial
- CasesTreatment being tested
140 children with H. pylori-persistent infection, who will receive eradication therapy
Treatment: Lansoprazole, Amoxicillin, Clarithromycin, and Metronidazole
- ControlsNo study treatment, for comparison
70 children with H. pylori-persistent infection, who will not receive eradication therapy
- Non infected ControlsNo study treatment, for comparison
60 adolescents with no H. pylori infection, they will not receive eradication therapy
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized "Screen and Treat" Helicobacter Pylori Eradication Trial in 14-18 Years Old Adolescents Residing in Three Regions of Chile: Effectiveness and Microbiological-host Implications
- Criteria questions
- Built from NCT05926804, who can take part
- Publications
- Record updated
- 17 December 2025